InMed Pharmaceuticals Inc - IMLFF

InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops novel and cannabinoid-based therapies. The company’s lead product is INM-750, a topical cannabinoid product candidate to treat epidermolysis bullosa (EB). The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, cancer, arthritis disease areas, and others. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-750 targeted as a therapy in EB and other dermatological and wound-healing applications; and a research and development collaboration agreement with ATERA SAS to develop 3D human skin models of EB to evaluate the in vitro drug efficacy of INM-750. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.